Literature DB >> 23497421

Reliability and validity of the Chinese version of the Pediatric Quality Of Life InventoryTM (PedsQLTM) 3.0 neuromuscular module in children with Duchenne muscular dystrophy.

Jun Hu1, Li Jiang, Siqi Hong, Li Cheng, Min Kong, Yuanzhen Ye.   

Abstract

BACKGROUND: The Pediatric Quality of Life Inventory(TM) (PedsQL(TM)) is a widely used instrument to measure pediatric health-related quality of life (HRQOL) in children aged 2 to 18 years. The current study aimed to evaluate the reliability and validity of the Chinese version of the PedsQL(TM) 3.0 Neuromuscular Module in children with Duchenne muscular dystrophy (DMD).
METHODS: The PedsQL(TM) 3.0 Neuromuscular Module was translated into Chinese following PedsQL(TM) Measurement Model Translation Methodology. The Chinese version scale was administered to 56 children with DMD and their parents, and the psychometric properties were evaluated.
RESULTS: The missing value percentages for each item of the Chinese version scale ranged from 0.00% to 0.54%. Internal consistency reliability approached or exceeded the minimum reliability standard of α = 0.7 (child α = 0.81, parent α = 0.86). Test-retest reliability was satisfactory, with intraclass correlation coefficients (ICCs) of 0.66 for children and 0.88 for parents (P < 0.01). Correlation coefficients between iteims and their hypothesized subscales were higher than those with other subscales (P < 0.05). The subscale of "About My/My Child's Neuromuscular Disease" significantly related to mobility and stair climbing status (Child t = 2.21, Parent t = 2.83, P < 0.05). The inter-correlations among the Chinese version of the PedsQL(TM) 3.0 Neuromuscular Module and the PedsQL(TM) 4.0 Generic Core Scales had medium to large effect sizes (P < 0.05). The child self-report scores were in moderate agreement with the parent proxy-report scores (ICC = 0.51, P < 0.05).
CONCLUSIONS: The Chinese version of the PedsQLTM 3.0 Neuromuscular Module has acceptable psychometric properties. It is a reliable measure of disease-specific HRQOL in Chinese children with DMD.

Entities:  

Mesh:

Year:  2013        PMID: 23497421      PMCID: PMC3606306          DOI: 10.1186/1477-7525-11-47

Source DB:  PubMed          Journal:  Health Qual Life Outcomes        ISSN: 1477-7525            Impact factor:   3.186


Background

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood and affects 1:3500 live male births [1]. DMD is caused by mutations (typically deletions) in the dystrophin gene on the X chromosome [2]. Since the gene was cloned in 1986, many strategies for treatment have been proposed and tested in animal models, as well as human subjects [3]. Although there are no specific DMD treatments, corticosteroid, nutrition, respiratory, cardiac, orthopedic, rehabilitative, and psychosocial interventions have improved function, quality of life, health, and longevity. Thus, children diagnosed with DMD may be able to reach the fourth decade of life, which is a significant improvement over the historical DMD life expectancy [4-8]. Health-related quality of life (HRQOL) is increasingly acknowledged as an important health outcome measure in clinical trials and health services research and evaluation involving children with neuromuscular disorders [9-12]. However, one challenge in measuring pediatric HRQOL is that the instrument must account for physical, emotional, social, and cognitive development that takes place during childhood and adolescence. In addition, questionnaires should provide the required information [13]. There is an emerging perspective that both generic and disease-specific HRQOL measures should be administered to pediatric patients with chronic health conditions in order to comprehensively evaluate patient HRQOL [14,15]. The Pediatric Quality of Life Inventory (PedsQLTM) Measurement Model was designed to integrate the relative merits of a generic core instrument with disease-specific modules [11,12,16-19]. The PedsQLTM Measurement Model was designed to develop and test brief measures for the broadest age group empirically feasible, including child self-report for young children [20,21]. The PedsQLTM 4.0 Generic Core Scales was specifically intended for application in healthy and patient populations [22]. It has been translated into many languages and widely used in more than 60 countries [23]. The Chinese version of the PedsQLTM 4.0 Generic Core Scales has been developed and psychometrically evaluated [24], but the Chinese version PedsQLTM 3.0 Neuromuscular Module for measuring HRQOL dimensions in children ages 2 to 18 years with neuromuscular disorders [10-12] has not been assessed for reliability and validity. The aim of the current study was to investigate the psychometric properties of the Chinese version of the PedsQLTM 3.0 Neuromuscular Module in children with DMD for use in conjunction with the Chinese version of the PedsQLTM 4.0 Generic Core Scales.

Methods

Subjects

This study was carried out in China between December 2009 and December 2011. Children aged 2 to 18 years with DMD and their parents were recruited through the Children’s Hospital, Chongqing Medical University. The diagnosis of DMD was initially based on their clinical history and neuromuscular findings and was confirmed by DNA testing or muscular biopsy. Children were excluded from this study if they had other chronic diseases or major developmental disorders. Families who did not agree to participate were also excluded. A total of 56 families were included, and informed consent forms were signed by all subjects and their parents. It was approved in compliance with the Helsinki Declaration by the Ethics Committee of Children's Hospital, Chongqing Medical University. The average age of the 56 male DMD patients was 7.54 (standard deviation [SD] = 4.06; range 2–13 years. Six were ages 2–4, 18 were ages 5–7, and 32 were ages 8–13. The sample was classified into two grades using the Vignos scale for lower extremities [25]. Thirty-seven (66.07%) children could climb stairs, but 19 could not.

Measures

PedsQLTM 3.0 neuromuscular module

The module encompasses three scales: 1) About My/My Child’s Neuromuscular Disease (17 items), 2) Communication (3 items), and 3) About Our Family Resources (5 items) [11,12]. The scale is comprised of parallel child self-report and parent proxy-report formats for children aged 5 to 18 years, and a parent proxy-report format for children ages 2 to 4 years. It is divided into seven forms, including child self-report formats for ages 5–7, 8–12, and 13–18 and parent proxy-report formats for ages 2–4, 5–7, 8–12, and 13–18. The young child form (ages 5–7 years) does not contain the “Communication” or “About Our Family Resources” Scale. Items in all forms are essentially identical but contain slightly different language for first or third person tense. The participants are asked how much of a problem each item had been during the past month. Responses are rated on a 5-point Likert scale across child self-report for children, teens, and parent proxy-reports (0 = never a problem, 1 = almost never a problem, 2 = sometimes a problem, 3 = often a problem, 4 = almost always a problem). Items are linearly transformed to a 0 to 100 scale (0 = 100, 1 = 75, 2 = 50, 3 = 25, and 4 = 0) so that higher scores indicate better HRQOL. Scale scores are computed as the sum of the items divided by the number of items answered. If more than 50% of the items in the scale are missing, the scale score is not computed [26].

PedsQLTM 4.0 generic core scales

The 23-item PedsQLTM 4.0 Generic Core Scales encompass: 1) Physical Functioning (8 items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School Functioning (5 items) [20,22,24]. The formats, instructions, Likert scales, and scoring methods are the same as those of the PedsQLTM 3.0 Neuromuscular Module. To create the Psychosocial Health Summary Score, the mean is computed as the sum of the items divided by the number of items answered in the Emotional, Social, and School Functioning Subscales.

Procedure

The PedsQLTM Measurement Model Translation Methodology was strictly followed in the linguistic translation process of the PedsQLTM 3.0 Neuromuscular Module in this study [27]. It is summarized as the procedure of Forward Translation - Backward Translation – Preliminary Test - Field Test. The instruments were independently translated into Chinese by a pediatrician and a medical English teacher, both of whom were fluent in English, and a multidisciplinary team reviewed both drafts. A single reconciled Chinese version was developed after discussion. It was translated back into English by a bilingual pediatrician. Then, a comparison between the versions was made to detect any misunderstandings or mistranslations, and a second Chinese version was written [24]. Cognitive debriefing was conducted with six children with DMD and their parents to confirm that the final Chinese version was understandable and acceptable. Reports for all stages were sent to and accepted by Mapi Research Institute in Lyon, France, on behalf of Dr. James W. Varni, the copyright owner of the PedsQLTM.

Data collection

Three physicians were trained as interviewers before the formal start of investigation. Participants completed the Chinese version of the PedsQLTM 3.0 Neuromuscular Module and the PedsQLTM 4.0 Generic Core Scales separately during hospitalization or an outpatient department visit. Paper-and-pencil questionnaires were self-administered for parents and for children ages 8 to 18 years and interview-administered for children ages 5–7 years. The interviewers were available to assist if the parents/children had questions on semantic or conceptual understanding. In the 56 parent questionnaires, 43 were completed by both parents together at the same time, and 13 by a single parent only. For test-retest reliability, a subset of (n =30) completed the PedsQLTM measures a second time 4–6 weeks later during a routinely scheduled clinic visit if they had suffered no adverse events since the first visit.

Data analysis

Data were analyzed with SPSS 17.0 for Windows. Descriptive analysis was used to report the demographic characteristics of children with DMD. The presence of floor and ceiling effects, which was the percentage of scores at the extremes and provided information on the distribution in a scale, was assessed for the Chinese version of the PedsQLTM 3.0 Neuromuscular Module. Continuous variables are presented as mean and standard deviation (mean ± SD). Categorical variables are shown as observed frequencies and proportions. Feasibility was determined from the percentage of missing values [28]. Scale internal consistency reliability for the Chinese version scale was determined at baseline by calculating Cronbach’s alpha coefficient [29]. Scales with reliabilities ≥0.70 are recommended for comparing patient groups, while a reliability criterion of 0.90 is recommended for analyzing individual patient scores [30,31]. Test-retest reliability for the Chinese version scale was assessed for a subset of the sample (n = 30) using intraclass correlation coefficients (ICCs) [32,33]. Patients and their parents were assessed an average of 35.82 days (SD = 10.36) after baseline. ICCs ≤0.40 were designated as poor to fair agreement, 0.41-0.60 moderate agreement, 0.61-0.80 good agreement, and 0.81-1.00 excellent agreement [32-34]. Multitrait scaling analysis for the Chinese version scale was conducted at baseline using Pearson correlation analysis to determine the item-subscale correlations. Good scaling success was indicated if the correlation between an item and its hypothesized subscale was stronger than those with other subscales [35]. Construct validity for the Chinese version scale was determined utilizing the known-groups method [33], which compares scale scores across groups known to differ in the health construct being investigated. Because of the small number of patients in one category, we used an independent sample t-test to compare the ability to climb stairs (yes vs. no) with the baseline Neuromuscular Module scores to perform the construct validity. Based on previous findings regarding the association with patient HRQOL, we hypothesized that the “About My/My Child’s Neuromuscular Disease” subscale would be correlated to stair climbing status, with higher QOL higher for patients who could climb stairs compared with those who could not [11,12]. Additional construct validity was examined through an analysis of intercorrelations among Neuromuscular Module Scores, Generic Core Scales, and Summary Scores [30]. We hypothesized greater disease-specific symptoms or problems would correlate with lower overall generic HRQOL based on the conceptualization of disease-specific symptoms as causal indicators of generic HRQOL [36]. Pearson Product Moment Correlation coefficients are designated as small (0.10-0.29), medium (0.30-0.49), and large (≥0.50) [37]. Agreement between child self-reports and parent proxy-reports of the Chinese version scale was determined through ICCs [38], which offers an index of absolute agreement because it takes into account the ratio between subject variability and total variability [38,39].

Results

Descriptive analysis

A total of 50 children and 56 parents completed the Chinese version of the PedsQLTM 3.0 Neuromuscular Module questionnaire, and the average time was about 5 minutes. Table 1 displays the means, standard deviations, and floor and ceiling effects for each subscale score. Ceiling effects in both child self- and parent proxy-reports ranged from 1.9-24.7%, with highest values in the “About My/My Child’s Neuromuscular Disease” subscale. Floor effects ranged from 1.2-14.6%, with a notably high value for the “Communication” subscale.
Table 1

Reliability and descriptive statistics of the Chinese version of the PedsQLTM 3.0 neuromuscular module for DMD

ScalenαMeanSD% floor% ceiling
Child self-report
 
 
 
 
 
 
 Total scale
32
0.81
53.64
10.55
2.7
19.5
About My Neuromuscular Disease
50
0.87
71.24
12.06
1.3
24.7
 Communication
32
0.80
39.06
22.54
16.7
1.9
 About Our Family Resources
32
0.73
52.50
15.76
1.7
3.8
Parent proxy-report
 
 
 
 
 
 
 Total scale
56
0.86
52.88
9.34
2.9
16.2
 About My Child’s Neuromuscular Disease
56
0.87
71.06
11.23
1.2
22.5
 Communication
56
0.83
37.50
20.41
14.6
2.1
 About Our Family Resources560.8550.0915.061.63.3

Note: Higher values denote better HRQOL.

% Floor/% Ceiling, the percentage of scores at the extremes of the scaling range; α, Cronbach’s alpha coefficient; SD, standard deviation.

Reliability and descriptive statistics of the Chinese version of the PedsQLTM 3.0 neuromuscular module for DMD Note: Higher values denote better HRQOL. % Floor/% Ceiling, the percentage of scores at the extremes of the scaling range; α, Cronbach’s alpha coefficient; SD, standard deviation.

Feasibility

The percentage of missing item responses for all scales was 0.54% and 0.31% for the child self-report and parent proxy-reports, respectively.

Internal consistency reliability

Internal consistency reliability coefficients are presented in Table 1. All child self-report and parent proxy-report scales exceeded the minimum reliability standard of 0.70 required for group comparisons.

Test-retest reliability

ICCs for test-retest reliability of the Chinese version scale are presented in Table 2. The majority of these ICCs had good to excellent reliability.
Table 2

ICCs for test-retest reliability of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD

ScaleChild self-report test-retest reliability ICCParent proxy-report test-retest reliability ICC
Total scale
0.66Δ
0.88Δ
About My/My Child’s Neuromuscular Disease
0.59Δ
0.85Δ
Communication
0.48*
0.76Δ
About Our Family Resources0.59Δ0.80Δ

Note: *P < 0.05, ΔP < 0.01.

ICC, intraclass correlation designated as ≤ 0.40 poor to fair agreement; 0.41-0.60 moderate agreement; 0.61-0.80 good agreement; and 0.81-1.00 excellent agreement.

ICCs for test-retest reliability of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD Note: *P < 0.05, ΔP < 0.01. ICC, intraclass correlation designated as ≤ 0.40 poor to fair agreement; 0.41-0.60 moderate agreement; 0.61-0.80 good agreement; and 0.81-1.00 excellent agreement.

Item-subscale correlations

Pearson correlation coefficients between items and subscale scores are presented in Table 3. We found that most items had moderate to strong correlations with their hypothesized subscales, which were higher than those with other subscales (P < 0.05).
Table 3

Item-subscale correlations of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD

Subscales & Items
Child self-report
Parent proxy-report
 ANCFRANCFR
About My/My Child’s Neuromuscular Disease (AN)
 
 
 
 
 
 
 It is hard to breathe
0.05
0.02
0.05
0.12
0.17
0.04
 Get sick easily
0.05
0.18
0.22
0.09
0.14
0.21
 Get sores and/or rashes
0.29
0.17
0.03
0.27
0.19
0.10
 Legs hurt
0.73
0.37
0.15
0.78
0.30
0.65
 Feel tired
0.80
0.14
0.21
0.77
0.12
0.51
 Back feel stiff
0.59
0.16
0.01
0.63
0.29
0.43
 Wake up tired
0.74
0.04
0.00
0.71
0.16
0.56
 Hands are weak
0.63
0.28
0.13
0.62
0.15
0.54
 Hard to use the bathroom
0.71
0.43
0.31
0.69
0.36
0.30
 Hard to gain or lose weight when one wants to
0.65
0.10
0.13
0.68
0.25
0.57
 Hard to use my hands
0.69
0.31
0.03
0.78
0.07
0.56
 Hard to swallow food
0.11
0.20
0.15
0.01
0.46
0.04
 Takes a long time to bathe or shower
0.70
0.00
0.07
0.71
0.25
0.56
 Get hurt accidentally
0.59
0.20
0.01
0.59
0.08
0.29
 Take a long time to eat
0.48
0.14
0.19
0.48
0.21
0.28
 Hard to turn oneself during the night
0.70
0.08
0.03
0.69
0.39
0.47
 Hard to go places with one’s equipment
0.66
0.22
0.36
0.61
0.46
0.37
Communication (C)
 
 
 
 
 
 
 Hard to tell the doctors and nurses how I feel
0.28
0.81
0.19
0.26
0.83
0.18
 Hard to ask the doctors and nurses questions
0.09
0.87
0.28
0.35
0.89
0.12
 Hard to explain the illness to other people
0.13
0.87
0.16
0.21
0.87
0.02
About Our Family Resources (FR)
 
 
 
 
 
 
 Hard for my family to plan activities like vacations
0.13
0.18
0.53
0.55
0.17
0.69
 Hard for my family to get enough rest
0.12
0.23
0.76
0.54
0.04
0.80
 I think money is a problem in our family
0.03
0.19
0.82
0.46
0.10
0.87
 I think my family has a lot of problems
0.01
0.17
0.84
0.64
0.06
0.79
 Do not have the equipment one needs0.050.140.700.520.090.80

Note: Pearson’s product moment correlations are designated as small (0.10), medium (0.30), and large (0.50).

Underlined values represent correlations between items and their hypothesized subscales.

AN, About My Neuromuscular Disease; C, Communication; FR, About Our Family Resources.

Item-subscale correlations of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD Note: Pearson’s product moment correlations are designated as small (0.10), medium (0.30), and large (0.50). Underlined values represent correlations between items and their hypothesized subscales. AN, About My Neuromuscular Disease; C, Communication; FR, About Our Family Resources.

Construct validity

Construct validity was assessed by comparing stair climbing mobility groups (climb stairs and non-climb) and is presented in Table 4. The a priori hypothesis that “About My/My Child’s Neuromuscular Disease” subscale would be significantly related to mobility was confirmed for both child self-report and parent proxy-report. The means increased for children who could climb stairs and those who could not for all of the Chinese version subscale scores. The inter-correlations between the Generic Core Scales and Summary Scores with the Neuromuscular Module are shown in Table 5. The majority of intercorrelations were in the medium to large range, supporting construct validity (P < 0.05).
Table 4

The known-groups method test comparing stair climbing status of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD

Scale
Can climb stairs
Cannot climb stairs
Independent sample t-test
 nMean (SD)nMean (SD)tP
Child self-report
 
 
 
 
 
 
 Total score
13
57.58 (11.24)
19
50.42 (8.20)
2.07
0.05
 About My Neuromuscular Disease
31
75.49 (11.85)
19
68.15 (11.44)
2.21
0.03
 Communication
13
43.33 (22.97)
19
35.29 (22.15)
1.01
0.32
 About Our Family Resources
13
54.00 (12.98)
19
51.18 (18.16)
0.5
0.62
Parent proxy-report
 
 
 
 
 
 
 Total score
37
55.66 (7.89)
19
48.26 (12.10)
2.50
0.02
 About My Child’s Neuromuscular Disease
37
74.16 (10.34)
19
65.90 (10.97)
2.83
0.01
 Communication
37
40.24 (19.85)
19
32.94 (21.00)
1.30
0.20
 About Our Family Resources3752.57 (11.72)1945.95 (19.01)1.620.11
Table 5

Pearson’s product moment correlations among the Chinese version of the PedsQLTMScales for DMD

ScaleTGPHPsyHEFSFSchFTNANCFR
PedsQLTM Generic Core Scales
 
 
 
 
 
 
 
 
 
 
Total Generic Core (TG)
---
0.43
0.56
0.60
0.67
0.74
0.67
0.14
0.61
0.28
Physical Health (PH)
0.47
---
0.55
0.44
0.43
0.50
0.43
0.28
0.22
0.25
Psychosocial Health (PsyH)
0.61
0.49
---
0.50
0.72
0.61
0.28
0.14
0.55
0.45
Emotional Functioning (EF)
0.41
0.33
0.31
---
0.48
0.38
0.48
0.10
0.50
0.12
Social Functioning (SF)
0.78
0.56
0.40
0.65
---
0.26
0.40
0.15
0.68
0.51
School Functioning (SchF)
0.67
0.46
0.60
0.61
0.66
---
0.24
0.22
0.49
0.37
PedsQLTM Neuromuscular Module
 
 
 
 
 
 
 
 
 
 
Total Neuromuscular Module (TN)
0.60
0.52
0.50
0.55
0.58
0.57
---
0.25
0.44
0.25
About My/My Child’s Neuromuscular Disease (AN)
0.39
0.38
0.23
0.46
0.30
0.40
0.30
---
0.20
0.27
Communication (C)
0.39
0.66
0.41
0.27
0.45
0.36
0.45
0.27
---
0.01
About Our Family Resources (FR)0.110.010.210.040.180.340.180.100.20---

Note: Pearson’s product moment correlations for child self-report and parent proxy-report are presented above and below the diagonal dashed lines, respectively.

Pearson’s product moment correlations are designated as small (0.10), medium (0.30), and large (0.50).

Underlined values represent correlations between child self-report and parent proxy-report subscales.

TG, Total Generic Core; PH, Physical Health; PsyH, Psychosocial Health; EF, Emotional Functioning; SF, Social Functioning; SchF, School Functioning; TN, Total Neuromuscular Module; AN, About My Neuromuscular Disease; C, Communication; FR, About Our Family Resources.

The known-groups method test comparing stair climbing status of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD Pearson’s product moment correlations among the Chinese version of the PedsQLTMScales for DMD Note: Pearson’s product moment correlations for child self-report and parent proxy-report are presented above and below the diagonal dashed lines, respectively. Pearson’s product moment correlations are designated as small (0.10), medium (0.30), and large (0.50). Underlined values represent correlations between child self-report and parent proxy-report subscales. TG, Total Generic Core; PH, Physical Health; PsyH, Psychosocial Health; EF, Emotional Functioning; SF, Social Functioning; SchF, School Functioning; TN, Total Neuromuscular Module; AN, About My Neuromuscular Disease; C, Communication; FR, About Our Family Resources.

Parent/child agreement

ICCs of the Chinese version scale are presented in Table 6. Most inter-correlations of subscales between child self-report and parent proxy-report were in the moderate agreement range. The greatest overall agreement was observed for the Total scale (0.51).
Table 6

ICCs of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD

ScaleParent–child agreement ICC
Total scale
0.51*
About My/My Child’s Neuromuscular Disease
0.49Δ
Communication
0.21
About Our Family Resources0.49*

Note: *P < 0.05, ΔP < 0.01.

ICC = intraclass correlation, ICCs are designated as ≤ 0.40 poor to fair agreement, 0.41-0.60 moderate agreement, 0.61-0.80 good agreement, and 0.81-1.00 excellent agreement.

ICCs of the Chinese version of the PedsQLTM3.0 neuromuscular module for DMD Note: *P < 0.05, ΔP < 0.01. ICC = intraclass correlation, ICCs are designated as ≤ 0.40 poor to fair agreement, 0.41-0.60 moderate agreement, 0.61-0.80 good agreement, and 0.81-1.00 excellent agreement.

Discussion

The PedsQLTM 3.0 Neuromuscular Module is a PedsQLTM disease-specific modules designed to measure the neuromuscular specific HRQOL of pediatric patients. It has satisfactory psychometric properties for both the child self-report and the parent proxy-report and is appropriate for children in a broad age range. The data described here support the feasibility, reliability, and validity of the Chinese version of the PedsQLTM 3.0 Neuromuscular Module in children with DMD living in mainland China. To our knowledge, it is also the first time that the PedsQLTM 3.0 Neuromuscular Module was tested on Chinese children with DMD. There were minimal missing item responses in the Chinese scale, indicating that children and their parents were able to provide good-quality data regarding pediatric HRQOL. However, our results show that there were several items, i.e., “hard to gain or lose weight when one wants to” and “do not have the equipment one needs,” with missing responses. Notably, the percentage of missing values was primarily attributable to 2–7 year old children. The reason may be that younger children had difficulty understand these questions, that most of them could not gain or lose weight, or that they did not require equipments because they were still able to walk. Regardless, this finding is consistent with those of the prior studies with other PedsQLTM disease-specific modules [40] and indicates that some modifications for items of these subscales are necessary in toddler and young child versions. In addition, the highest ceiling effect was observed in the “About My/My Child’s Neuromuscular Disease” subscale. It is understandable in a mixed participant with different disease severity, where the majority of children with DMD (66.07%) could climb stairs which would be expected to influence markedly their daily lives. There was also a notable floor effect in the “Communication” subscale. It suggests that children with DMD lack good communication; this problem requires the joint efforts of the clinicians and the community. Internal consistency reliabilities of the Chinese version exceeded the minimum alpha coefficient standard of 0.70 required for group comparisons for all child self-report and parent proxy-report scales. These findings are consistent with reliability estimates for the original English version [11,12], indicating acceptable reliability of the Chinese version scale. Although Cronbach’s alpha represents the lower limit of reliability of a measurement instrument and is a conservative estimate of actual reliability [41], scales that did not meet the 0.70 standard should only be used for descriptive analyses. Overall, responses to the Chinese version scale were in the good to excellent agreement range across a 4–6 week period and correlated significantly, supporting test-retest reliability and demonstrating that the Chinese version scale is stable over time. In order to evaluate the item-subscale correlations of the Chinese version scale, we analyzed Pearson correlations between items and subscale scores. The results of correlations between items and their hypothesized subscales were high, but those between items and other subscales were weak, indicating good scaling success for child self-reports and parent proxy-reports. Construct validity was assessed with the Known-Groups Method of comparing mobility groups (climb stairs vs. non-climb). The a priori hypothesis that “About My/My Child’s Neuromuscular Disease” subscale would be significantly related to mobility was confirmed for both child self-report and parent proxy-report. The subscales of “Communication” and “About Our Family Resources” showed unqualified discriminate abilities, probably due to the relatively small sample size, and both are recommended for further testing. Construct validity was further tested by analyzing inter-correlations among the Chinese version scale Scores and the PedsQLTM 4.0 Generic Core Scales and Summary Scores. Consistent with the conceptualization of disease-specific symptoms as causal indicators of generic HRQOL, the majority of inter-correlations among the Chinese version scale and the Generic Core Scales were in the medium to large range, supporting construct validity. Regarding the agreement between child self-report and parent proxy-report of the Chinese version scale, our data were mostly in the moderate agreement range. This is consistent with both the adult and pediatric literature, suggesting that information provided by proxy-respondents is not equivalent to that reported by patients [42,43]. Imperfect agreement between child self-report and parent proxy-report has been consistently documented in HRQOL measurements of children with and without chronic illness [44,45], particularly for less observable or internal symptoms. This study has several limitations that should be considered when interpreting the results. In mainland China, many children with DMD have refused or abandoned treatment for financial reasons, and HRQOL information about these patients is lacking. All of the subjects in this study were recruited in a large city (Chongqing) in mainland China; determining whether the scale can be generalized to other regions will require further studies in other areas. Information on non-participants’ and participants’ socioeconomic status was not available and could affect our findings. The test-retest data were obtained with an interval of around 4–6 weeks, which was considered to be long enough to make the children with DMD and their parents forget their answers from the first test. However, a potential limitation of the long interval was the possibility of the occurrence of positive or negative events affecting the participants. In addition, the small sample size did not allow us to perform a factor analysis; correlation coefficients from factor analyses tend to be less reliable when estimated from small sample sizes [46]. Future studies with larger samples will allow factor analysis with this population. Finally, we did not evaluate the responsiveness, which is used to detect HRQOL changes while a patient’s health status changes over time and can be regarded as additional evidence of instrument validity [33]. Thus, further longitudinal studies are advised to assess responsiveness.

Conclusions

This study is important because it is the first time the PedsQLTM 3.0 Neuromuscular Module has been applied in China. Our results provide reasonable evidence that the Chinese version of the PedsQLTM 3.0 Neuromuscular Module has acceptable psychometric properties. Given the potential differences between patient and proxy reports, we recommend that the pediatric patient self-report should be collected as the primary patient-reported outcome, and the parent proxy-report should be collected as a secondary patient-reported outcome. Further longitudinal studies with larger samples should be carried out to conduct factor analysis and testing responsiveness of the Chinese version scale, particularly in rural areas.

Abbreviations

DMD: Duchenne muscular dystrophy; HRQOL: Health-related quality of life; PedsQLTM: Pediatric quality of life inventoryTM; ICC: Intraclass correlation.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

JH conceptualized and designed the study; acquired, analyzed, and interpreted the data; and drafted the manuscript. SH and LC conceptualized and designed the study, acquired data, and revised the manuscript. MK and YY conceptualized and designed the study; acquired, analyzed, and interpreted the data; and revised the manuscript. LJ conceptualized and designed the study, supervised the data analysis, and revised the manuscript. All authors read and approved the final manuscript.
  37 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Coefficient alpha and the reliability of composite measurements.

Authors:  M R Novick; C Lewis
Journal:  Psychometrika       Date:  1967-03       Impact factor: 2.500

3.  Child/adolescent behavioral and emotional problems: implications of cross-informant correlations for situational specificity.

Authors:  T M Achenbach; S H McConaughy; C T Howell
Journal:  Psychol Bull       Date:  1987-03       Impact factor: 17.737

Review 4.  The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review.

Authors:  M A Sprangers; N K Aaronson
Journal:  J Clin Epidemiol       Date:  1992-07       Impact factor: 6.437

5.  Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy.

Authors:  L M Kunkel; J F Hejtmancik; C T Caskey; A Speer; A P Monaco; W Middlesworth; C A Colletti; C Bertelson; U Müller; M Bresnan; F Shapiro; U Tantravahi; J Speer; S A Latt; R Bartlett; M A Pericak-Vance; A D Roses; M W Thompson; P N Ray; R G Worton; K H Fischbeck; P Gallano; M Coulon; C Duros; J Boue; C Junien; J Chelly; G Hamard; M Jeanpierre; M Lambert; J C Kaplan; A Emery; H Dorkins; S McGlade; K E Davies; C Boehm; B Arveiler; C Lemaire; G J Morgan; M J Denton; J Amos; M Bobrow; F Benham; E Boswinkel; C Cole; V Dubowitz; K Hart; S Hodgson; L Johnson; A Walker; L Roncuzzi; A Ferlini; C Nobile; G Romeo; D E Wilcox; N A Affara; M A Ferguson-Smith; M Lindolf; H Kaariainen; A de la Chapelle; V Ionasescu; C Searby; R Ionasescu; E Bakker; G J van Ommen; P L Pearson; C R Greenberg; J L Hamerton; K Wrogemann; R A Doherty; R Polakowska; C Hyser; S Quirk; N Thomas; J F Harper; B T Darras; U Francke
Journal:  Nature       Date:  1986 Jul 3-9       Impact factor: 49.962

6.  The PedsQL in pediatric asthma: reliability and validity of the Pediatric Quality of Life Inventory generic core scales and asthma module.

Authors:  James W Varni; Tasha M Burwinkle; Michael A Rapoff; Jodi L Kamps; Nancy Olson
Journal:  J Behav Med       Date:  2004-06

7.  The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life.

Authors:  M A Sprangers; A Cull; K Bjordal; M Groenvold; N K Aaronson
Journal:  Qual Life Res       Date:  1993-08       Impact factor: 4.147

8.  Validation of the German version of the Pediatric Quality of Life Inventory (PedsQL) in childhood cancer patients off treatment and children with epilepsy.

Authors:  R Felder-Puig; E Frey; K Proksch; J W Varni; H Gadner; R Topf
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

9.  Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures.

Authors:  J M Florence; S Pandya; W M King; J D Robison; L C Signore; M Wentzell; M A Province
Journal:  Phys Ther       Date:  1984-01

Review 10.  Population frequencies of inherited neuromuscular diseases--a world survey.

Authors:  A E Emery
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

View more
  10 in total

1.  Measuring quality of life in muscular dystrophy.

Authors:  Carla M Bann; Richard T Abresch; Barbara Biesecker; Kristin Caspers Conway; Chad Heatwole; Holly Peay; Peter Scal; Jonathan Strober; Karen Uzark; Jodi Wolff; Marjorie Margolis; Angela Blackwell; Natalie Street; Angela Montesanti; Julie Bolen
Journal:  Neurology       Date:  2015-02-06       Impact factor: 9.910

2.  Quality of Life of Latino and Non-Latino Youth With Sickle Cell Disease as Reported by Parents and Youth.

Authors:  Jennel C Osborne; Nancy S Green; Arlene M Smaldone
Journal:  Hisp Health Care Int       Date:  2020-03-03

Review 3.  Measuring quality of life in children with spinal muscular atrophy: a systematic literature review.

Authors:  Shalvaree Vaidya; Stefan Boes
Journal:  Qual Life Res       Date:  2018-07-24       Impact factor: 4.147

4.  Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies.

Authors:  Minal S Jain; Katherine Meilleur; Eunhee Kim; Gina Norato; Melissa Waite; Leslie Nelson; Michelle McGuire; Tina Duong; Katherine Keller; Donovan J Lott; Allan Glanzman; Kristy Rose; Marion Main; Courtney Fiorini; Irene Chrismer; Melody Linton; Monal Punjabi; Jeffrey Elliott; Fatoumata Tounkara; Ruhi Vasavada; Ranjani Logaraj; Jocelyn Winkert; Sandra Donkervoort; Meganne Leach; Jahannaz Dastgir; Linda Hynan; Carmel Nichols; Elizabeth Hartnett; Gilberto M Averion; James C Collins; Eunice S Kim; Angela Kokkinis; Alice Schindler; Kristen Zukosky; Robert Fee; Veronica Hinton; Payam Mohassel; Diana Bharucha-Goebel; Carole Vuillerot; Peter McGraw; Mark Barton; Joseph Fontana; Anne Rutkowski; A Reghan Foley; Carsten G Bönnemann
Journal:  Neurology       Date:  2019-10-25       Impact factor: 9.910

5.  Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study.

Authors:  Erik Landfeldt; Peter Lindgren; Christopher F Bell; Michela Guglieri; Volker Straub; Hanns Lochmüller; Katharine Bushby
Journal:  Dev Med Child Neurol       Date:  2015-10-19       Impact factor: 5.449

6.  Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy: A Review.

Authors:  Yi Wei; Kathy Speechley; Craig Campbell
Journal:  J Neuromuscul Dis       Date:  2015-09-02

Review 7.  Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy.

Authors:  Erik Landfeldt; Hanns Lochmüller; Peter Lindgren
Journal:  Orphanet J Rare Dis       Date:  2019-04-02       Impact factor: 4.123

8.  Translation and validation of Indonesian version of Pediatric Quality of Life Inventory™ (PedsQL™) Neuromuscular Module.

Authors:  Guswan Wiwaha; Dian M Sari; Vitriana Biben; Deni K Sunjaya; Dany Hilmanto
Journal:  Health Qual Life Outcomes       Date:  2022-02-24       Impact factor: 3.186

9.  The Associations Between Accelerometer-Measured Physical Activity Levels and Mental Health in Children and Adolescents with Intellectual Disabilities During the COVID-19 Pandemic.

Authors:  Wen Yang; Ming Hui Li; Jane Jie Yu; Stephen Heung-Sang Wong; Raymond Kim-Wai Sum; Cindy Hui-Ping Sit
Journal:  J Autism Dev Disord       Date:  2022-10-01

10.  Measuring and valuing health-related quality of life among children and adolescents in mainland China--a pilot study.

Authors:  Fei Xu; Gang Chen; Katherine Stevens; HaiRong Zhou; ShengXiang Qi; ZhiYong Wang; Xin Hong; XuPeng Chen; HuaFeng Yang; ChenChen Wang; Julie Ratcliffe
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.